Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  anastrozole
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-25 of 47 for your search:
Start Over
STARS Breast Trial (Study of Anastrozole and Radiotherapy Sequencing Pilot)
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: STARS-Pilot (05/55 Graham), NCT00126360
Adjuvant Endocrine Therapy for Estrogen Receptor-beta Positive Triple Negative Breast Cancer
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: PUMCH-breast-TNBC, NCT02089854
Safety of OFS Combined With AI Endocrine Therapy in Chinese Premenopausal Breast Cancer Patients
Phase: Phase IV
Type: Supportive care, Treatment
Status: Active
Age: 18 and over, premenopausal
Sponsor: Other
Protocol IDs: RJBC1503, NCT02440230
Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: Under 70
Sponsor: Other
Protocol IDs: CDR0000635986, COL-MNEMOSYNE, 2007-12, INCA-RECF0899, EUDRACT-2008-003620-32, MNEMOSYNE, NCT00893061
STARS Breast Trial (Study of Anastrozole and Radiotherapy Sequencing)
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: TROG 08.06, ACTRN12610000307000, NCT00887380
Study of Exemestane After Anastrozole or Letrozole Treatment of Postmenopausal Women With Hormone Responsive Breast Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: Postmenopausal
Sponsor: Other
Protocol IDs: SHBCC0701, NCT00902954
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
Phase: Phase III
Type: Health services research, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02623, CDR0000692475, SWOG-S1007, S1007, U10CA180888, U10CA032102, NCT01272037
Influence of Aromatase Inhibitors and GnRH Analogs to Treat Uterine Leiomyoma by Vaginal Hysterectomy
Phase: Phase III
Type: Treatment
Status: Active
Age: 40 to 60
Sponsor: Other
Protocol IDs: FMRPUSP-UROGIN-001, NCT01280045
Adjuvant AI Combined With Zoladex
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over (Premenopausal)
Sponsor: Other
Protocol IDs: CBCSG002, NCT01352091
Study of Arimidex and Radiotherapy Sequencing
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: BR-RT-002, NCT01402193
Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: A221102, CDR0000730083, NCI-2012-00719, U10CA037447, CALGB-A221102, NCCTG-N10C7, NCT01573442
DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: DETECT III, 2010-024238-46, NCT01619111
Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With Poor Prognosis, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving 3 Years of Adjuvant Hormone Therapy
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UNIRAD, 2012-003187-44, UC-0140/1208, NCT01805271
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: A011106, NCI-2013-01340, U10CA031946, NCT01953588
A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 15417, I3Y-MC-JPBM, 2014-001502-18, NCT02246621
Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 59
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLEE011E2301, NCT02278120
Detect V / CHEVENDO (Chemo vs. Endo)
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 and ove
Sponsor: Other
Protocol IDs: D-V, 2014-002249-22, NCT02344472
A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZDO530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 20080325, SCCC-2008002, NCT01216176
A Trial of AZD4547 for Breast Cancer That is Oestrogen Receptor Positive and Has Got Worse Despite Having Anastrozole or Letrozole
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 25 and over
Sponsor: Other
Protocol IDs: C/23/2011, 2011-000454-32, NCT01791985
Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: H 20431, IRUSFULV0060, NCT00570323
Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000595712, SINGAPORE-NCC0706, NCC0706, NCT00687648
Pre-operative Hormonal Treatment for Hormone Receptor Positive Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: N08AFT, EudraCT; 2008-000644-13, NCT00738777
Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 84 and under
Sponsor: Other
Protocol IDs: CDR0000633329, IB-HORGEN, IB-IB2007-26, INCA-RECF0514, EUDRACT-2007-004216-31, ZENECA-IB-HORGEN, HORGEN, NCT00871858
Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: 11595, IRUSANAS0092, NCT00921115
Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal Women
Phase: Phase II
Type: Treatment
Status: Active
Age: 55 and under
Sponsor: Other
Protocol IDs: 2010-04-001, NCT01266213
Start Over